Global, randomized, double-blind, multicenter, placebo-controlled study of 225 patients1-3

93% of patients treated with ONPATTRO® (patisiran) and 62% of patients treated with placebo completed 18 months of the assigned treatment2
aStudy patients had a diagnosis of hATTR amyloidosis with polyneuropathy caused by any transthyretin (TTR) mutation, had FAP stage 1 or 2 disease, had a Neuropathy Impairment Score (NIS) of 5-130, and were permitted to have previously used tetramer stabilizers. bEndpoints assessed at 18 months.
When patients completed their participation
in the 18-month APOLLO study,
99% of eligible patients
elected to enter the OLE study.3,c
c186 of 187 patients.
The APOLLO study included a diverse patient population
- Global study1,3
225 patients from 19 countries
- Broad age range3
24 to 83 years old (median 62 years)
- Multiple mutations2,3
39 different TTR mutations were represented in the study population
- Prior treatment3
53% of patients had previously been treated with tafamidis or diflunisal
Disease characteristics of
patient population2,d
Stage 1 polyneuropathy2
Unimpaired ambulation
(mostly mild sensory, motor, and
autonomic neuropathy in lower limbs)
Stage 2 polyneuropathy2
Assistance with ambulation required
(mostly moderate impairment progression
to the lower limbs, upper limbs, and trunk)
dFAP stage percentages do not add up to 100% due to inclusion of 1 stage 3 patient.3

Participants in APOLLO reflect
real-world patient
demographics, demonstrating the potential for ONPATTRO
to treat polyneuropathy manifestations in a variety of adults with hATTR amyloidosis.3